Company profile
Ticker
FDMT
Exchange
Website
CEO
Dr. David H. Kirn M.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
4D Molecular Therapeutics Inc, 4D Molecular Therapeutics Inc.
SEC CIK
Corporate docs
IRS number
473506994
FDMT stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Other Events
10 Feb 25
8-K
Results of Operations and Financial Condition
10 Jan 25
8-K
Unregistered Sales of Equity Securities
11 Dec 24
10-Q
2024 Q3
Quarterly report
13 Nov 24
8-K
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights
13 Nov 24
8-K
Other Events
18 Sep 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights
8 Aug 24
8-K
Regulation FD Disclosure
23 Jul 24
8-K
Other Events
17 Jul 24
Latest ownership filings
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 25
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 25
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 25
SC 13G/A
JANUS HENDERSON GROUP PLC
14 Feb 25
SC 13G/A
Deep Track Capital, LP
14 Feb 25
SC 13G/A
GOLDMAN SACHS GROUP INC
10 Feb 25
4
Peter Kolchinsky
10 Dec 24
SC 13G/A
BlackRock, Inc.
6 Dec 24
3
Peter Kolchinsky
25 Nov 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
15 Nov 24
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 187.54 mm | 187.54 mm | 187.54 mm | 187.54 mm | 187.54 mm | 187.54 mm |
Cash burn (monthly) | 507.33 k | 7.34 mm | 17.04 mm | 14.03 mm | 9.80 mm | 9.45 mm |
Cash used (since last report) | 2.38 mm | 34.40 mm | 79.82 mm | 65.71 mm | 45.88 mm | 44.25 mm |
Cash remaining | 185.16 mm | 153.14 mm | 107.72 mm | 121.82 mm | 141.66 mm | 143.29 mm |
Runway (months of cash) | 365.0 | 20.8 | 6.3 | 8.7 | 14.5 | 15.2 |
Institutional ownership, Q4 2024
13F holders | Current |
---|---|
Total holders | 146 |
Opened positions | 32 |
Closed positions | 28 |
Increased positions | 51 |
Reduced positions | 46 |
13F shares | Current |
---|---|
Total value | 257.89 bn |
Total shares | 54.65 mm |
Total puts | 32.70 k |
Total calls | 120.50 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 4.92 mm | $27.41 bn |
Biotechnology Value Fund L P | 4.83 mm | $27.07 mm |
Ra Capital Management | 4.56 mm | $25.42 bn |
GS The Goldman Sachs Group, Inc. | 4.27 mm | $23.81 bn |
VR Adviser | 2.95 mm | $16.44 bn |
Venrock Healthcare Capital Partners III | 2.95 mm | $16.53 mm |
Vanguard | 2.86 mm | $15.93 bn |
BVF | 2.67 mm | $14.88 bn |
JHG Janus Henderson | 2.25 mm | $12.54 bn |
MS Morgan Stanley | 1.86 mm | $10.38 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Dec 24 | Ra Capital Management | Common Stock | Other | Dispose J | Yes | No | 0 | 535,000 | 0.00 | 4,563,211 |
9 Dec 24 | Ra Capital Management | Pre-Funded Warrants Common Stock | Other | Acquire J | Yes | No | 0.0001 | 535,000 | 53.50 | 3,610,000 |
8 Nov 24 | Partners L P/il BVF | Common Stock, $0.0001 par value | Other | Dispose J | No | No | 0 | 240,000 | 0.00 | 87,911 |
8 Nov 24 | Partners L P/il BVF | Common Stock, $0.0001 par value | Other | Dispose J | No | No | 0 | 2,378,000 | 0.00 | 662,970 |
8 Nov 24 | Partners L P/il BVF | Common Stock, $0.0001 par value | Other | Dispose J | No | No | 0 | 3,062,000 | 0.00 | 830,237 |
8 Nov 24 | Partners L P/il BVF | Pre-Funded Warrant Common Stock, $0.0001 par value | Other | Acquire J | No | No | 0.0001 | 240,000 | 24.00 | 240,000 |
8 Nov 24 | Partners L P/il BVF | Pre-Funded Warrant Common Stock, $0.0001 par value | Other | Acquire J | No | No | 0.0001 | 2,378,000 | 237.80 | 2,378,000 |
8 Nov 24 | Partners L P/il BVF | Pre-Funded Warrant Common Stock, $0.0001 par value | Other | Acquire J | No | No | 0.0001 | 3,062,000 | 306.20 | 3,062,000 |
16 Sep 24 | Scott Bizily | Common Stock | Sell | Dispose S | No | Yes | 16.33 | 500 | 8.16 k | 6,781 |
16 Sep 24 | Scott Bizily | Common Stock | Option exercise | Acquire M | No | Yes | 6.49 | 500 | 3.25 k | 7,281 |
News
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $30
1w ago
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
1w ago
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts
1w ago
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
1w ago
Reported Saturday, 4DMT Shares 52-Week Findings From Phase 2b PRISM Wet AMD Study And Long-Term Durability Data Supporting 4D-150 4FRONT Global Registration Program
1w ago
Press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
1w ago
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
1w ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
2w ago
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
3w ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
3w ago